PASG
Passage Bio, Inc. NASDAQ Listed Feb 28, 2020$4.08
Mkt Cap $13.1M
52w Low $3.95
0.8% of range
52w High $20.00
50d MA $7.71
200d MA $8.59
P/E (TTM)
-0.3x
EV/EBITDA
-0.4x
P/B
0.8x
Debt/Equity
1.3x
ROE
-242.7%
P/FCF
-1.2x
RSI (14)
—
ATR (14)
—
Beta
1.76
50d MA
$7.71
200d MA
$8.59
Avg Volume
71.4K
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
One Commerce Square · Philadelphia, PA 19103 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | AMC | -2.19 | -4.08 | -86.3% | 8.00 | +5.2% | +5.5% | -3.8% | +3.4% | +4.6% | -3.2% | — |
| Nov 10, 2025 | AMC | -2.64 | -2.44 | +7.6% | 6.71 | -4.5% | +14.8% | +21.8% | -9.1% | +3.8% | +1.5% | — |
| Aug 12, 2025 | AMC | -4.00 | -2.96 | +26.0% | 5.61 | -1.6% | +13.7% | +19.0% | -8.4% | +3.9% | -4.0% | — |
| May 13, 2025 | AMC | -4.80 | -5.00 | -4.2% | 5.90 | +1.7% | -9.7% | +11.6% | +1.5% | -1.3% | +5.4% | — |
| Mar 4, 2025 | AMC | -0.21 | -0.20 | +4.8% | 8.51 | +5.5% | +10.5% | +0.0% | -2.1% | -11.3% | +1.2% | — |
| Nov 13, 2024 | AMC | -0.23 | -0.31 | -34.8% | 11.64 | +5.3% | +1.4% | -12.0% | -9.2% | +2.3% | +6.5% | — |
| Aug 8, 2024 | AMC | -0.31 | -0.26 | +16.1% | 15.60 | +1.3% | -6.2% | +8.2% | -1.1% | -4.3% | +4.1% | — |
| May 14, 2024 | AMC | -0.37 | -0.30 | +18.9% | 26.60 | +0.0% | -3.8% | +4.7% | -1.5% | -0.8% | -2.3% | — |
| Mar 4, 2024 | AMC | -0.41 | -0.30 | +26.8% | 34.20 | -5.8% | -1.8% | +1.8% | -6.4% | -9.4% | -3.4% | — |
| Nov 13, 2023 | AMC | -0.47 | -0.49 | -4.3% | 12.00 | +5.0% | +10.0% | -4.9% | -4.1% | -0.3% | +4.9% | — |
| Aug 7, 2023 | AMC | -0.48 | -0.44 | +8.3% | 16.70 | +5.4% | +2.0% | -4.8% | +1.1% | -0.6% | -1.0% | — |
| May 11, 2023 | AMC | -0.49 | -0.63 | -28.6% | 20.00 | +1.0% | +1.0% | +2.0% | -2.9% | -1.8% | -0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | TD Cowen | Downgrade | Buy → Hold | — | $6.25 | $6.38 | +2.1% | -1.1% | -0.8% | -3.8% | -1.0% | -2.2% |
| Apr 21 | Chardan Capital Markets | Downgrade | Buy → Neutral | $7 | $6.25 | $6.38 | +2.1% | -1.1% | -0.8% | -3.8% | -1.0% | -2.2% |
| Apr 21 | Chardan Capital | Downgrade | Buy → Neutral | — | $6.25 | $6.38 | +2.1% | -1.1% | -0.8% | -3.8% | -1.0% | -2.2% |
| Apr 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $6.25 | $6.38 | +2.1% | -1.1% | -0.8% | -3.8% | -1.0% | -2.2% |
| Apr 21 | Wedbush | Downgrade | Outperform → Neutral | $8 | $6.25 | $6.38 | +2.1% | -1.1% | -0.8% | -3.8% | -1.0% | -2.2% |
| Mar 4 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.00 | $8.42 | +5.2% | +5.5% | -3.8% | +3.4% | +4.6% | -3.2% |
| Nov 12 | Chardan Capital | Maintains | Buy → Buy | — | $7.70 | $8.05 | +4.5% | +21.8% | -9.1% | +3.8% | +1.5% | -5.1% |
| Aug 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.38 | $6.50 | +1.9% | +19.0% | -8.4% | +3.9% | -4.0% | +11.0% |
| Aug 14 | Guggenheim | Maintains | Buy → Buy | — | $6.38 | $6.50 | +1.9% | +19.0% | -8.4% | +3.9% | -4.0% | +11.0% |
| Aug 13 | Wedbush | Maintains | Outperform → Outperform | — | $5.61 | $5.52 | -1.6% | +13.7% | +19.0% | -8.4% | +3.9% | -4.0% |
| Jun 24 | Chardan Capital | Maintains | Buy → Buy | — | $6.70 | $7.10 | +6.0% | +4.9% | -7.3% | +1.2% | +0.3% | +21.0% |
| Mar 4 | Chardan Capital | Maintains | Buy → Buy | — | $9.60 | $9.40 | -2.1% | -11.4% | +10.5% | +0.0% | -2.1% | -11.3% |
| Nov 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.64 | $12.26 | +5.3% | +1.4% | -12.0% | -9.2% | +2.3% | +6.5% |
| Nov 14 | Chardan Capital | Maintains | Buy → Buy | — | $11.64 | $12.26 | +5.3% | +1.4% | -12.0% | -9.2% | +2.3% | +6.5% |
| Sep 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $14.61 | $14.80 | +1.3% | -0.5% | -3.6% | -0.1% | -2.7% | -5.1% |
| May 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $26.60 | $26.60 | +0.0% | -3.8% | +4.7% | -1.5% | -0.8% | -2.3% |
| Mar 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $34.20 | $32.20 | -5.8% | -1.8% | +1.8% | -6.4% | -9.4% | -3.4% |
| Nov 14 | Raymond James | Maintains | Outperform → Outperform | — | $12.00 | $12.60 | +5.0% | +10.0% | -4.9% | -4.1% | -0.3% | +4.9% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $16.70 | $17.60 | +5.4% | +2.0% | -4.8% | +1.1% | -0.6% | -1.0% |
| May 12 | Raymond James | Maintains | Outperform → Outperform | — | $20.00 | $20.20 | +1.0% | +1.0% | +2.0% | -2.9% | -1.8% | -0.5% |
| Dec 15 | Chardan Capital | Maintains | Buy → Buy | — | $25.00 | $24.40 | -2.4% | -2.4% | -1.6% | -1.7% | +1.7% | +0.0% |
| Nov 11 | Citigroup | Maintains | Buy → Buy | — | $26.60 | $27.00 | +1.5% | +9.8% | +1.4% | -0.7% | -4.1% | +0.7% |
| Nov 11 | Guggenheim | Maintains | Buy → Buy | — | $26.60 | $27.00 | +1.5% | +9.8% | +1.4% | -0.7% | -4.1% | +0.7% |
| Nov 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $24.00 | $24.60 | +2.5% | -1.7% | +1.7% | +10.8% | +9.8% | +1.4% |
| May 17 | Raymond James | Maintains | Outperform → Outperform | — | $33.80 | $35.40 | +4.7% | +10.7% | -5.3% | +3.4% | +10.4% | -6.4% |
| May 17 | Citigroup | Maintains | Buy → Buy | — | $33.80 | $35.40 | +4.7% | +10.7% | -5.3% | +3.4% | +10.4% | -6.4% |
| Mar 8 | JP Morgan | Downgrade | Overweight → Neutral | — | $56.40 | $54.00 | -4.3% | -5.7% | +10.9% | -0.2% | +0.2% | -4.7% |
| Mar 4 | Raymond James | Maintains | Outperform → Outperform | — | $61.00 | $60.80 | -0.3% | -3.9% | -3.8% | -5.7% | +10.9% | -0.2% |
| Jan 19 | Goldman Sachs | Downgrade | Buy → Neutral | — | $108.00 | $103.00 | -4.6% | -8.5% | -2.8% | -0.2% | +3.3% | -0.6% |
| Jul 1 | Raymond James | Maintains | Outperform → Outperform | — | $264.80 | $277.80 | +4.9% | +12.9% | +3.8% | -14.6% | -1.9% | +4.2% |
| Jun 15 | BTIG | Maintains | Buy → Buy | — | $289.40 | $304.00 | +5.0% | +0.4% | -0.6% | +0.6% | -1.2% | -2.5% |
| Mar 8 | Chardan Capital | Maintains | Buy → Buy | — | $396.60 | $419.80 | +5.8% | -1.9% | +6.7% | -0.6% | +3.2% | +0.2% |
| Mar 4 | Goldman Sachs | Upgrade | Neutral → Buy | — | $399.20 | $433.20 | +8.5% | -2.7% | +2.1% | -1.9% | +6.7% | -0.6% |
| Feb 4 | Guggenheim | Maintains | Buy → Buy | — | $412.00 | $423.00 | +2.7% | +6.2% | -1.3% | -4.0% | -3.1% | -1.2% |
| Jan 4 | JP Morgan | Upgrade | Neutral → Overweight | — | $511.40 | $523.40 | +2.3% | +10.0% | -1.6% | -0.3% | +1.7% | -2.3% |
| Dec 11 | Citigroup | Maintains | Neutral → Neutral | — | $557.00 | $540.00 | -3.1% | -1.4% | -2.2% | +0.1% | +10.7% | -6.0% |
| Aug 14 | JP Morgan | Downgrade | Overweight → Neutral | — | $307.40 | $281.80 | -8.3% | -7.4% | +5.4% | -4.1% | -4.8% | +6.1% |
| Jun 25 | Goldman Sachs | Downgrade | Buy → Neutral | — | $674.00 | $642.20 | -4.7% | +4.0% | -19.0% | -2.3% | -1.5% | -4.6% |
| May 11 | Chardan Capital | Maintains | Buy → Buy | — | $406.40 | $404.60 | -0.4% | +1.1% | +3.3% | +2.5% | +1.8% | -3.7% |
| Mar 25 | Chardan Capital | Maintains | Buy → Buy | — | $280.40 | $282.80 | +0.9% | +5.1% | -7.5% | -8.1% | +25.5% | +0.2% |
| Mar 24 | Goldman Sachs | Maintains | Buy → Buy | — | $241.20 | $270.00 | +11.9% | +16.3% | +5.1% | -7.5% | -8.1% | +25.5% |
No insider trades available.
8-K
Passage Bio, Inc. -- 8-K Filing
Passage Bio (PASG) is undergoing workforce reduction and restructuring while evaluating strategic alternatives, with potential financial impacts from termination benefits and uncertain outcomes.
Apr 28
8-K · 7.01
! Medium
Passage Bio, Inc. -- 8-K 7.01: Regulation FD Disclosure
Passage Bio's PBFT02 gene therapy showed a 64% reduction in brain atrophy over 12 months in FTD patients compared to untreated controls, suggesting potential disease-slowing efficacy in frontotemporal dementia.
Apr 20
8-K · 1.02
!! High
Unknown — 8-K 1.02: Material Agreement Terminated
PASG terminated a material agreement, likely reducing revenue or operational capacity, which investors should monitor for updates on replacement partnerships or financial impact guidance.
Mar 10
8-K · 7.01
! Medium
Passage Bio, Inc. -- 8-K 7.01: Regulation FD Disclosure
Passage Bio updated its corporate presentation, suggesting the company refreshed its investor messaging and strategic positioning for stakeholders.
Mar 3
Data updated apr 26, 2026 6:39pm
· Source: massive.com